Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.

ABSTRACT:

Background

Programmed cell death protein-1 (PD-1) or its ligand PD-L1 monoclonal antibodies, opening a new era of tumor immunotherapy, and they have significantly improved the overall survival of many patients with advanced solid tumors. However, in addition to its effectiveness, we should also pay attention to its adverse effects. The instructions of the PD-1 inhibitor camrelizumab clearly indicate that reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse reaction; it is common for many immune checkpoint inhibitors (ICIs). Here we describe a case that anlotinib improved RCCEP induced by anti-PD-1 blockade camrelizumab with some focus on further management of this symptoms.

Case description

A 57-year-old man with squamous cell carcinoma o

SUBMITTER: Wu R 

PROVIDER: S-EPMC9459630 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature